NASDAQ : RNAZ
TransCode Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.63 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 27.60M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 7.92M | 5.77M | 5.95M | 7.15M | 8.40M | 3.40M |
| Research & Development | 17.44M | 13.42M | 9.71M | 12.26M | 10.23M | 2.75M |
| Operating Expenses | 25.36M | 19.19M | 15.66M | 19.42M | 18.63M | 6.15M |
| Operating Income | -25.36M | -19.19M | -15.66M | -19.42M | -18.63M | -6.15M |
| Interest Expense | -6.50K | -6.62K | -26.81K | -55.90K | -31.99K | -95.07K |
| Interest & Investment Income | 222.96K | 79.20K | 684.00 | 5.29K | 20.41K | 664.00 |
| Currency Exchange Gain (Loss) | -94.99K | -112.06K | -57.06K | |||
| Other Non Operating Income (Expenses) | 601.22K | -8.00M | -1.01M | 923.03K | 1.08M | -594.78K |
| EBT Excluding Unusual Items | -24.64M | -27.23M | -16.76M | -18.55M | -17.56M | -6.84M |
| Merger & Restructuring Charges | -8.79M | -8.79M | ||||
| Gain (Loss) on Sale of Assets | 500.00 | -3.08K | ||||
| Other Unusual Items | 1.47M | 1.58M | ||||
| Pretax Income | -42.38M | -34.44M | -16.75M | -18.55M | -17.56M | -6.84M |
| Income Tax Expense | 457.68K | 226.07K | ||||
| Net Income | -42.83M | -34.66M | -16.75M | -18.55M | -17.56M | -6.84M |
| Preferred Dividends & Other Adjustments | 3.45M | 1.61M | 30.60K | |||
| Net Income to Common | -46.28M | -36.27M | -16.79M | -18.55M | -17.56M | -6.84M |
| Shares Outstanding (Basic) | 906.18K | 689.71K | 12.56K | |||
| Shares Outstanding (Diluted) | 906.18K | 689.71K | 12.56K | |||
| EPS (Basic) | -51.08 | -52.59 | -1,336.64 | |||
| EPS (Diluted) | -51.08 | -52.59 | -1,336.64 | |||
| Free Cash Flow | -22.61M | -19.52M | -13.36M | -18.11M | -15.86M | -5.52M |
| Free Cash Flow Per Share | -24.95 | -28.31 | -1,063.68 | |||
| EBITDA | -25.26M | -19.12M | -15.57M | -19.30M | -18.54M | -6.11M |
| D&A For EBITDA | 97.43K | 76.45K | 90.89K | 123.48K | 98.61K | 42.47K |
| EBIT | -25.36M | -19.19M | -15.66M | -19.42M | -18.63M | -6.15M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.38M | 17.81M | 5.81M | 2.77M | 4.97M | 20.83M |
| Short-Term Investments | 9.41K | 9.41K | ||||
| Cash & Short-Term Investments | 8.38M | 17.81M | 5.81M | 2.77M | 4.98M | 20.84M |
| Other Receivables | 638.00 | 953.10K | ||||
| Receivables | 638.00 | 953.10K | ||||
| Prepaid Expenses | 95.64K | 317.96K | 342.30K | 547.67K | 1.38M | 1.46M |
| Other Current Assets | 2.16M | 2.90M | 939.98K | 1.14M | 1.02M | 441.59K |
| Total Current Assets | 10.64M | 21.98M | 7.09M | 4.46M | 7.38M | 22.73M |
| Property, Plant & Equipment | 322.81K | 370.68K | 89.31K | 602.40K | 208.58K | 206.27K |
| Goodwill | 25.74M | 25.74M | ||||
| Other Intangible Assets | 114.30M | 114.30M | ||||
| Other Long-Term Assets | 111.86K | 111.86K | ||||
| Total Assets | 151.01M | 162.40M | 7.29M | 5.17M | 7.59M | 22.94M |
| Accrued Expenses | 4.68M | 3.49M | 2.71M | 3.05M | 4.35M | 2.50M |
| Short-Term Debt | 652.41K | |||||
| Current Portion of Leases | 38.29K | 412.28K | ||||
| Current Unearned Revenue | 63.95K | 25.41K | 27.06K | 30.53K | ||
| Total Current Liabilities | 5.40M | 3.49M | 2.77M | 3.49M | 4.35M | 2.53M |
| Long-Term Leases | 38.29K | |||||
| Long-Term Deferred Tax Liabilities | 457.68K | 226.07K | ||||
| Other Long-Term Liabilities | 6.80M | 6.80M | 6.54M | |||
| Total Liabilities | 12.65M | 10.52M | 9.31M | 3.53M | 4.35M | 2.53M |
| Common Stock | 101.00 | 92.00 | 4.00 | 2.00 | 2.00 | 1.29K |
| Additional Paid-In Capital | 94.70M | 108.20M | 61.18M | 48.06M | 31.11M | 30.71M |
| Retained Earnings | -122.40M | -97.86M | -63.20M | -46.42M | -27.87M | -10.31M |
| Total Common Equity | -27.70M | 10.34M | -2.02M | 1.64M | 3.24M | 20.40M |
| Shareholders' Equity | 138.36M | 151.88M | -2.02M | 1.64M | 3.24M | 20.40M |
| Total Liabilities & Equity | 151.01M | 162.40M | 7.29M | 5.17M | 7.59M | 22.94M |
| Total Debt | 652.41K | 38.29K | 450.57K | |||
| Net Cash (Debt) | 7.73M | 17.81M | 5.77M | 2.32M | 4.98M | 20.84M |
| Net Cash Per Share | 8.53 | 25.83 | 459.69 | |||
| Filing Date Shares Outstanding | 16.93M | 916.97K | 833.62K | |||
| Total Common Shares Outstanding | 1.01M | 916.97K | 36.75K | |||
| Working Capital | 5.24M | 18.49M | 4.32M | 964.85K | 3.03M | 20.20M |
| Book Value Per Share | -27.38 | 11.27 | -54.93 | |||
| Tangible Book Value | -167.74M | -129.71M | -2.02M | 1.64M | 3.24M | 20.40M |
| Tangible Book Value Per Share | -165.82 | -141.45 | -54.93 | |||
| Machinery | 757.94K | 757.94K | 362.39K | 384.05K | 348.44K | 247.52K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -42.83M | -34.66M | -16.75M | -18.55M | -17.56M | -6.84M |
| Depreciation & Amortization | 97.43K | 114.18K | 534.86K | 516.75K | 98.61K | 42.47K |
| Loss (Gain) From Sale of Assets | 3.08K | |||||
| Stock-Based Compensation | 196.19K | 485.43K | 1.70M | 1.04M | 395.33K | 186.00K |
| Other Operating Activities | 5.42M | 14.53M | 1.54M | 912.58K | ||
| Change in Accounts Payable | 2.55M | 216.54K | -343.12K | -1.30M | 1.84M | 2.29M |
| Change in Unearned Revenue | 63.95K | -25.41K | -1.65K | 27.06K | -30.53K | 30.53K |
| Change in Other Net Operating Assets | 1.02M | -401.63K | -6.71K | 186.90K | -504.67K | -1.88M |
| Operating Cash Flow | -22.61M | -19.52M | -13.34M | -18.07M | -15.76M | -5.27M |
| Capital Expenditures | -6.66K | -6.66K | -21.76K | -35.61K | -100.92K | -254.82K |
| Sale of Property, Plant & Equipment | 3.00K | |||||
| Cash Acquisitions | 2.22K | 2.22K | ||||
| Investing Cash Flow | -4.44K | -4.44K | -21.76K | -35.61K | -100.92K | -251.82K |
| Net Debt Issued (Repaid) | 950.00K | |||||
| Issuance of Common Stock | 1.00 | 8.85M | 16.40M | 15.91M | 5.99K | 26.38M |
| Other Financing Activities | -860.94K | |||||
| Financing Cash Flow | 23.62M | 31.52M | 16.40M | 15.91M | 5.99K | 25.52M |
| Net Cash Flow | 1.01M | 12.00M | 3.04M | -2.20M | -15.86M | 20.00M |
| Free Cash Flow | -22.61M | -19.52M | -13.36M | -18.11M | -15.86M | -5.52M |
| Free Cash Flow Per Share | -24.95 | -28.31 | -1,063.68 | |||
| Levered Free Cash Flow | -13.78M | -13.53M | -7.53M | -11.21M | -9.96M | -3.70M |
| Unlevered Free Cash Flow | -13.77M | -13.53M | -7.51M | -11.17M | -9.94M | -3.64M |
| Cash Interest Paid | 6.50K | 6.50K | 16.63K | 32.86K | 37.12K | 17.87K |
| Change in Working Capital | 4.09M | 15.57K | -351.48K | -1.08M | 1.31M | 432.39K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 27.60M | 6.26M | 2.35M | 4.14M | 8.46M | 31.92M |
| Enterprise Value | 19.87M | 3.43M | 622.97K | -2.72M | -342.68K | 9.41M |
| Last Close Price | 1.63 | 6.83 | 94.36 | 6,091.00 | 497,486.69 | 1,877,587.00 |
| PB Ratio | 0.20 | 0.04 | -1.16 | 2.52 | 2.61 | 1.56 |
| P/TBV Ratio | 2.52 | 2.61 | 1.56 | |||
| Debt / Equity Ratio | 0.01 | -0.02 | 0.28 | |||
| Net Debt / Equity Ratio | -0.06 | -0.12 | 2.86 | -1.41 | -1.54 | -1.02 |
| Net Debt / EBITDA Ratio | 0.31 | 0.93 | 0.37 | 0.12 | 0.27 | 3.41 |
| Net Debt / FCF Ratio | 0.34 | 0.91 | 0.43 | 0.13 | 0.31 | 3.77 |
| Quick Ratio | 1.55 | 5.37 | 2.10 | 0.79 | 1.15 | 8.22 |
| Current Ratio | 1.97 | 6.29 | 2.56 | 1.28 | 1.70 | 8.97 |
| Return on Equity (ROE) | -59.28% | -46.26% | -759.85% | -148.57% | -80.53% | |
| Return on Assets (ROA) | -19.90% | -14.14% | -157.06% | -190.26% | -76.30% | -32.05% |
| Return on Capital Employed (ROCE) | -17.40% | -12.10% | -346.30% | -1,156.50% | -575.00% | -30.10% |
| Earnings Yield | -3,133.54% | -553.44% | -714.09% | -448.43% | -207.69% | -21.44% |
| FCF Yield | -81.94% | -311.72% | -569.30% | -437.89% | -187.57% | -17.30% |
| Buyback Yield / Dilution | -246.69% | -5,392.22% |